Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, Hong Kong, and China. For more information, visit www.deciphera.com.
DNS Made Easy, Mimecast, Outlook, Drupal, Amazon SES, Pantheon, New Relic, Google Tag Manager, Nginx, Mobile Friendly, Varnish, Vimeo